Welcome to LookChem.com Sign In|Join Free
  • or
Methyl 2-bromo-6-methylbenzoate is a chemical compound with the molecular formula C9H9BrO2. It is a methyl ester derivative of 2-bromo-6-methylbenzoic acid, containing a bromine atom and a methyl group. This colorless to pale yellow liquid with a pungent odor is commonly used as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. Additionally, it serves as a reagent in organic chemistry reactions, such as esterification and bromination. Due to its hazardous nature if ingested, inhaled, or absorbed through the skin, it requires careful handling and adherence to proper safety protocols.

99548-56-8

Post Buying Request

99548-56-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

99548-56-8 Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-bromo-6-methylbenzoate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 2-bromo-6-methylbenzoate is utilized as an intermediate in the production of agrochemicals, potentially enhancing the effectiveness of pesticides and other agricultural chemicals.
Used in Organic Chemistry Research:
Methyl 2-bromo-6-methylbenzoate is employed as a reagent in organic chemistry reactions, such as esterification and bromination, facilitating the synthesis of complex organic molecules for research and development purposes.

Check Digit Verification of cas no

The CAS Registry Mumber 99548-56-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,9,5,4 and 8 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 99548-56:
(7*9)+(6*9)+(5*5)+(4*4)+(3*8)+(2*5)+(1*6)=198
198 % 10 = 8
So 99548-56-8 is a valid CAS Registry Number.

99548-56-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name Methyl 2-Bromo-6-Methylbenzoate

1.2 Other means of identification

Product number -
Other names Methyl 2-bromo-6-methylbenzoate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:99548-56-8 SDS

99548-56-8Relevant academic research and scientific papers

ISOINDOLINES AS HDAC INHIBITORS

-

Paragraph 00123, (2019/11/12)

The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: (I) wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.

Supramolecular control of selectivity in hydroformylation of vinyl arenes: Easy access to valuable β-aldehyde intermediates

Dydio, Pawel,Reek, Joost N. H.

supporting information, p. 3878 - 3882 (2013/05/09)

Go against the flow! A rationally designed regioselective hydroformylation catalyst, [Rh/L], in which noncovalent ligand-substrate interactions allow the unprecedented reversal of selectivity from the typical α-aldehyde to the otherwise unfavored product β-aldehyde, is reported. This catalytic system opens up novel and sustainable synthetic pathways to important intermediates for the fine-chemicals industry.

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

-

, (2013/02/28)

The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders

PHARMACEUTICAL PRODUCT CONTAINING LACTAM OR BENZENE SULFONAMIDE COMPOUND

-

Page/Page column 101, (2012/06/01)

The present invention provides, for example, the following compounds as a pharmaceutical composition for treating diseases induced by production, secretion or deposition of amyloid β proteins. The present invention provides a pharmaceutical composition for suppressing amyloid β production comprising a compound of the formula: wherein A is a benzene ring, a pyridine ring or a pyrimidine ring, X is sultam, lactam, sulfonamide or the like, C is substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl or the like, R2, R3 and R4 are each independently hydrogen, halogen, hydroxy, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy or the like, its pharmaceutically acceptable salt or a solvate thereof.

Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer

Gandhi, Viraj B.,Luo, Yan,Liu, Xuesong,Shi, Yan,Klinghofer, Vered,Johnson, Eric F.,Park, Chang,Giranda, Vincent L.,Penning, Thomas D.,Zhu, Gui-Dong

scheme or table, p. 1023 - 1026 (2010/06/14)

Through conformational restriction of a benzamide by formation of a seven-membered hydrogen-bond with an oxindole carbonyl group, a series of PARP inhibitors was designed for appropriate orientation for binding to the PARP surface. This series of compound

Total synthesis of the aspercyclides

Pospisil, Jiri,Mueller, Christoph,Fuerstner, Alois

supporting information; experimental part, p. 5956 - 5968 (2010/03/03)

Two different approaches to the eleven-membered biaryl ether lactones of the aspercyclide family are disclosed. The core regions of these highly strained targets, which are able to interfere with the binding of immunoglobulinE to its high affinity receptor, can either be forged by ring-closing olefin metathesis (RCM) or by a highly diastereoselective chromium-mediated Nozaki-Hiyama-Kishi (NHK) reaction. Whereas the RCM approach turned out to be responsive to minor changes in the substitution pattern of the substrate, the NHK route is more generally applicable. The preparation of the required cyclization precursor 43 hinged on a palladium-catalyzed orthoiodination reaction of 2-methylbenzoic acid, an efficient copper-catalyzed Ullmann coupling, and a Takai-Utimoto olefination as the key steps. Moreover, the esterification of the 2,6-disubstituted benzoic acid 34 with the sterically hindered secondary alcohol 37 was far from trivial. However, this and related transformations were accomplished by recourse to the corresponding acid fluorides, which provided excellent yields in cases in which the more commonly used acid chlorides or mixed anhydrides failed to afford any of the desiredproducts.

POLY(ADP-RIBOSE)POLYMERASE INHIBITORS

-

Page/Page column 11, (2008/12/04)

Compounds which inhibit the activity of poly(ADP-ribose)polymerase, compositions containing the compounds and methods of treating diseases using the compounds is disclosed.

SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS

-

Page/Page column 52, (2008/06/13)

The present invention is directed to novel substituted dihydro-isoindolone compounds of formula (I): and forms thereof, wherein Ring A, X3, R1, R2, R3, R4 and R6 are as herein defined, and their synthesis and use as protein kinase inhibitors and interactions thereof.

Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use

-

Page/Page column 27, (2010/02/11)

Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Total synthesis of aspercyclide C

Fuerstner, Alois,Mueller, Christoph

, p. 5583 - 5585 (2007/10/03)

The first total synthesis of (+)-aspercyclide C (1) is reported using a kinetically controlled RCM reaction to form the 11-membered, unsaturated lactone ring of this bioactive diaryl ether macrolide. The Royal Society of Chemistry 2005.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 99548-56-8